Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Breast03
2024-514376-40-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of patritumab deruxtecan and pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (3 arms), sponsored by Merck & Co. Primary endpoints: Number of participants experiencing an adverse event, Number of participants with one or more dose-limiting toxicities and 2 more. Planned start Oct 2025; status: authorised.
02
Drugs
patritumab deruxtecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2024-514376-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514376-40-00.